Refractory Anemia With Excess of Blasts (RAEB) (DBCOND0054529)

Identifiers

Synonyms

Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts / RAEB / Refractory anemia with an excess of blasts / MDS-refractory anemia with excess blasts (RAEB) / Anemia, Refractory, With Excess of Blasts / Refractory anaemia with an excess of blasts / Refractory Anemia With Excess Blasts / Myelodysplastic syndrome with excess blasts / Refractory anemia with excess of blasts [RAEB] / Refractory anemia with excess of blasts, unspecified / Myelodysplastic syndrome with excess blasts (disorder) / Myelodysplastic syndrome with increased blasts (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Azacitidine	A pyrimidine nucleoside analogue used to treat certain subtypes of myelodysplastic syndrome.	DNA (cytosine-5)-methyltransferase 1target Cytidine deaminaseenzyme DNAtarget RNAtarget
Cedazuridine	A cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS).	Cytidine deaminasetarget
Decitabine	A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression.	DNAtarget DNA (cytosine-5)-methyltransferase 1target Deoxycytidine kinaseenzyme UMP-CMP kinaseenzyme Nucleoside diphosphokinaseenzyme Cytidine deaminaseenzyme DNA (cytosine-5)-methyltransferase 3Atarget DNA (cytosine-5)-methyltransferase 3Btarget Sodium/nucleoside cotransporter 1transporter Histone deacetylasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00809250	Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation	No drug interventions	treatment	1	completed
NCT02562443	Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA	Rigosertib	treatment	3	terminated
NCT01241500	Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts	Rigosertib	treatment	3	completed
NCT01463410	Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler	No drug interventions	Not Available	Not Available	terminated
NCT03175978	IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome	Methotrexate	treatment	1 / 2	terminated
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1 / 2	withdrawn
NCT00038051	Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies	No drug interventions	treatment	1	completed
NCT01461538	Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies	Brentuximab vedotin	treatment	2	completed
NCT00015990	Thalidomide in Treating Patients With Myelodysplastic Syndrome	Thalidomide	treatment	2	completed
NCT00005845	Tipifarnib in Treating Patients With Myelodysplastic Syndromes	Tipifarnib	treatment	1	completed
NCT00002798	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Aldesleukin Asparaginase Escherichia coli Aspartic acid Busulfan Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Etoposide Filgrastim Fludarabine Hydrocortisone Idarubicin Methotrexate Tioguanine	treatment	3	completed
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT01928537	Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine	Rigosertib	treatment	3	completed
NCT01831232	Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	Cytarabine Idarubicin Pravastatin	treatment	Not Available	completed
NCT00005942	Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy	Daunorubicin Semaxanib	treatment	1 / 2	completed
NCT00006213	BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	BMS-214662	treatment	1	completed
NCT00397813	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00004918	Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Incomplete Freund's adjuvant PR1 leukemia peptide vaccine Sargramostim	treatment	1 / 2	completed
NCT01165996	Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	2'-Deoxycytidine Decitabine	treatment	1 / 2	completed
NCT00278330	Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia	Alvocidib Vorinostat	treatment	1	completed
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT00104962	Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	Lenalidomide	treatment	1	completed
NCT01101880	Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm	Clofarabine Cytarabine Filgrastim	treatment	2	completed
NCT01146210	Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	completed
NCT00540995	Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer	Beta-D-Glucose Busulfan Etoposide	treatment	1 / 2	terminated
NCT00005064	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome	Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT00008177	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01607645	Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS	2'-Deoxycytidine Cytarabine Decitabine Idarubicin	treatment	2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Entinostat Sargramostim	treatment	2	completed
NCT01175785	Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	Cyclophosphamide Cyclosporine Dilanubicel Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00988715	Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01872819	Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay	No drug interventions	treatment	Not Available	completed
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	Menthol Temsirolimus	treatment	2	completed
NCT00589316	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	1	terminated
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Cytarabine Idarubicin Tipifarnib	treatment	1 / 2	completed
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	terminated
NCT00357565	Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	Busulfan Cyclosporine Filgrastim Fludarabine Melphalan Mycophenolate mofetil	treatment	2	active_not_recruiting
NCT00052520	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT02566304	Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Mycophenolic acid Tacrolimus	treatment	2	active_not_recruiting
NCT01300572	Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	Cyclosporine Fludarabine Indium Mycophenolate mofetil	treatment	1	completed
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed